UBS maintains Buy on BMY ahead of Ph3 IPF review
UBS says a deep dive into BMY’s Phase 3 IPF studies is coming up and keeps a Buy rating with an $80 price target.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.